Bio-Techne said pathologists now have access to its fully automated RNAscope technology, providing them with a new tool to evaluate disease biomarkers.
Only 2.5 percent of Americans have been tested for COVID-19, even as industry scrambles to increase testing capacity and a second wave of cases may hit in the fall.
The firm said it would use the funds for general corporate purposes, including potential future acquisitions, capital expenditures, and investments or loans.
Danaher President and CEO Thomas Joyce will retire in September and will be replaced by Rainer Blair, the current executive VP of the life sciences division.
